Pulmonary sarcomatoid carcinoma（PSC）is a rare type of non-small cell lung cancer，characterized by high invasiveness and heterogeneity. It is insensitive to traditional radiotherapy and chemotherapy，resulting in an extremely poor prognosis. Immunotherapy，as a landmark advancement in lung cancer treatment，provides a new direction for the treatment of PSC patients with driver gene negativity，offering hope for improving clinical outcomes. Based on this，this article provides a comprehensive review of the latest research progress on immunotherapy for PSC，encompassing both domestic and international studies.